ATE220331T1 - Cd40 bindendes protein zur stimulierung der immunantwort - Google Patents

Cd40 bindendes protein zur stimulierung der immunantwort

Info

Publication number
ATE220331T1
ATE220331T1 AT96909555T AT96909555T ATE220331T1 AT E220331 T1 ATE220331 T1 AT E220331T1 AT 96909555 T AT96909555 T AT 96909555T AT 96909555 T AT96909555 T AT 96909555T AT E220331 T1 ATE220331 T1 AT E220331T1
Authority
AT
Austria
Prior art keywords
immune response
binding protein
stimulate
individuals
pathogenic
Prior art date
Application number
AT96909555T
Other languages
English (en)
Inventor
Mark Alderson
Kim A Campbell
Mary K Kennedy
Charles R Maliszewski
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE220331T1 publication Critical patent/ATE220331T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
AT96909555T 1995-03-01 1996-02-29 Cd40 bindendes protein zur stimulierung der immunantwort ATE220331T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39623095A 1995-03-01 1995-03-01
PCT/US1996/002839 WO1996026735A1 (en) 1995-03-01 1996-02-29 Method for stimulating an immune response

Publications (1)

Publication Number Publication Date
ATE220331T1 true ATE220331T1 (de) 2002-07-15

Family

ID=23566398

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96909555T ATE220331T1 (de) 1995-03-01 1996-02-29 Cd40 bindendes protein zur stimulierung der immunantwort

Country Status (15)

Country Link
EP (1) EP0812206B1 (de)
JP (1) JP3657271B2 (de)
KR (1) KR19980702490A (de)
AT (1) ATE220331T1 (de)
AU (1) AU699291B2 (de)
CA (1) CA2213798C (de)
DE (1) DE69622259T2 (de)
DK (1) DK0812206T3 (de)
ES (1) ES2179187T3 (de)
FI (1) FI973484A7 (de)
MX (1) MX9706588A (de)
NO (1) NO973875L (de)
NZ (1) NZ305083A (de)
PT (1) PT812206E (de)
WO (1) WO1996026735A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999022008A1 (en) * 1997-10-27 1999-05-06 Sumitomo Electric Industries, Ltd. Inducer for production of antigen-specific antibody, expression vector containing gene therefor, and method of inducing production of antigen-specific antibody
AU2004199A (en) * 1997-12-19 1999-07-12 Immunex Corporation Method for reducing susceptibility to hiv infection
CN1212155C (zh) * 1998-05-23 2005-07-27 莱顿大学医学中心 用于治疗肿瘤的cd40结合分子和ctl肽
DE60136334D1 (en) 2000-02-02 2008-12-11 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
CN101522210B (zh) 2006-09-18 2017-03-22 阿肯色大学评议会 增强免疫应答的组合物和方法
WO2009059018A1 (en) 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
EP3097926B1 (de) 2007-11-01 2019-10-02 The Board of Trustees of the University of Arkansas Zusammensetzungen und verfahren zur verstärkung von immunreaktionen gegenüber eimeria
KR101638661B1 (ko) 2010-01-21 2016-07-11 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 백신 벡터 및 면역 반응을 강화시키는 방법
PL2579901T3 (pl) 2010-06-09 2020-02-28 The Board Of Trustees Of The University Of Arkansas Szczepionka i sposoby ograniczania infekcji campylobacter
MX339239B (es) 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
AU2013337903B2 (en) 2012-10-30 2018-08-16 Apexigen, Inc. Anti-CD40 antibodies and methods of use
BR112015019283B1 (pt) 2013-02-14 2023-12-19 The Board Of Trustees Of The University Of Arkansas Composições e métodos de aprimoramento de respostas imunes à eiméria ou infecção por eiméria limitadora
MY173901A (en) 2013-03-15 2020-02-26 Texas A & M Univ Sys Compositions and methods of enhancing immune responses to enteric pathogens
EP3744340A3 (de) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Zusammensetzungen und verfahren zur behandlung von krebs
EP3445783A2 (de) 2016-04-18 2019-02-27 Celldex Therapeutics, Inc. Agonistische antikörper zur bindung von humanem cd40 und verwendungen davon
BR112018072592A2 (pt) 2016-05-03 2019-04-16 The Board Of Trustees Of The University Of Arkansas vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0897983B1 (de) * 1991-10-25 2003-05-07 Immunex Corporation Antikörper gegen CD40-L
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
EP0724456B1 (de) * 1993-10-01 2003-12-10 Immunex Corporation Antikörper gegen cd40

Also Published As

Publication number Publication date
NZ305083A (en) 1999-06-29
WO1996026735A1 (en) 1996-09-06
EP0812206A1 (de) 1997-12-17
JP3657271B2 (ja) 2005-06-08
PT812206E (pt) 2002-11-29
KR19980702490A (ko) 1998-07-15
ES2179187T3 (es) 2003-01-16
DE69622259T2 (de) 2003-03-27
DE69622259D1 (de) 2002-08-14
DK0812206T3 (da) 2002-09-09
AU5301196A (en) 1996-09-18
NO973875L (no) 1997-10-31
MX9706588A (es) 1997-11-29
AU699291B2 (en) 1998-11-26
FI973484A0 (fi) 1997-08-25
FI973484L (fi) 1997-10-24
NO973875D0 (no) 1997-08-22
JPH11506418A (ja) 1999-06-08
EP0812206B1 (de) 2002-07-10
CA2213798A1 (en) 1996-09-06
CA2213798C (en) 2001-02-06
FI973484A7 (fi) 1997-10-24

Similar Documents

Publication Publication Date Title
ATE220331T1 (de) Cd40 bindendes protein zur stimulierung der immunantwort
ATE163195T1 (de) Lösliche liganden für cd40
NO963168L (no) Immunstimulatoriske monoklonale antistoffer
DK0724456T3 (da) CD40-Antistoffer
HUP9901874A2 (hu) Humán TNFalfa-t kötő antitestek
DE69129989D1 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
ATE245030T1 (de) Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
DE50114906D1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur stimulation von blutzellen, welche kein cd28 tragen
DE69738692D1 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGEN ZUR HEM
NO971059L (no) Modifiserte human-C3-proteiner
ATE410514T1 (de) Calciumbindende rekombinante antikörper gegen protein c
ATE442157T1 (de) Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten
ATE290881T1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
DE69803392D1 (de) Anti-cd40l immunotoxine zur behandlung von krankheiten
DE59611293D1 (de) Protein mit dnase-aktivität
DE69118702D1 (de) Neue verwendung eines monoklonalen antikörpers
DE59611353D1 (de) Transketolase-verwandtes protein
MX9602274A (es) Procedimiento para la preservacion de antigenos sin usar inhibidores enzimaticos y su aplicacion en metodos inmunologicos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee